WEIGHT-LOSS EVIDENCE
Semaglutide Weight Loss: The Trial Evidence
How much, how fast, how durable — and what the studies say happens when you stop. The headline number, then the honest fine print.
The short version
Semaglutide weight loss is real and large in the trials, but it comes with fine print worth knowing up front. In the main study, people lost about 15% of their body weight over roughly 16 months — far more than the placebo group [1]. Most of that comes from eating less, because the drug quiets hunger, not from burning more calories [4]. The catch: when people stop, much of the weight returns — about 11.6 percentage points within a year in one study [17]. Some of what is lost is muscle, not just fat [16]. And a newer drug, tirzepatide, beat it head-to-head [7]. The full evidence, with numbers and caveats, is below.
The headline number: STEP 1
The anchor for semaglutide weight loss is the STEP 1 trial (n=1,961). Once-weekly subcutaneous semaglutide 2.4 mg produced a mean body-weight change of -14.9% from baseline to week 68, versus -2.4% with placebo — a treatment difference of about 12.4 percentage points [1]. To put that in everyday terms, a person starting at 100 kg would, on average, be near 85 kg at the end. A 2025 review describes the broader program as a major advance in obesity treatment [10]. That is the result that moved GLP-1 weight management from incremental to transformative.
Why it works: less hunger, not more burn
The weight comes off mainly because semaglutide turns down appetite, not because it speeds metabolism. Rodent work mapped the drug reaching the brain's appetite hubs — the hypothalamic arcuate nucleus and the brainstem area postrema — where it activates the "full" neurons and quiets the "hungry" ones, lowering food intake and shifting food preference without lowering energy expenditure [4]. In human terms, people eat smaller portions and stop grazing because the drive to eat is muted. That is also why the most-reported real-world benefit is quieter "food noise," described on the effects page.
How durable is it?
Durability is the honest catch in semaglutide weight loss. The STEP 4 randomized-withdrawal design showed that continuing the drug led to continued loss, while switching to placebo led to regain. The STEP 1 extension put a number on stopping: participants regained a mean of about 11.6 percentage points of body weight within a year of discontinuation, and cardiometabolic improvements reverted toward baseline [17]. The lesson the trials teach is that this is a chronic-treatment model — the weight effect persists while the drug is taken and largely reverses when it is not.
What kind of weight comes off
Not all of the loss is fat. A STEP-program body-composition substudy using DXA scans found the weight lost with semaglutide 2.4 mg comprised both fat mass and a meaningful proportion of lean (muscle) mass [16]. Because rapid, large-magnitude weight loss can erode muscle, this has raised a sarcopenia concern — especially in older adults — and motivated research into adequate protein intake and resistance training to protect lean tissue. The lean-mass loss is the observed finding; the muscle-loss risk is a reasoned extrapolation from it.
How it compares for weight loss
On the specific question of weight, the newer drug currently leads. In the SURMOUNT-5 head-to-head (n=751) in adults with obesity, tirzepatide produced greater mean weight loss than semaglutide at 72 weeks: -20.2% versus -13.7% (P<0.001) [7]. That does not erase semaglutide's record — it carries the larger cardiovascular- and kidney-outcomes evidence and comes as both a pill and a shot [3][6]. The full, fair side-by-side is on the semaglutide vs tirzepatide page.
Who the weight-loss trials studied
Knowing who was in the trials helps read the numbers honestly. STEP 1 enrolled adults with overweight or obesity and no diabetes, and the -14.9% mean change was measured over 68 weeks with the drug paired with lifestyle support [1]. The result is an average across that population over that time — not a promise for any individual, and not a number that necessarily transfers to people outside those criteria. A 2025 review situates the STEP program as a major advance specifically in obesity treatment [10]. The weight effect has also been shown beyond adults: across the wider STEP program it produced clinically meaningful loss in additional groups, but each of those is its own trial with its own population, and this site reports the adult STEP 1 figure as the anchor.
Beyond the scale
The weight number is not the only reason these trials matter. In SELECT, in people with cardiovascular disease and obesity but no diabetes, semaglutide reduced major adverse cardiovascular events by 20% versus placebo (HR 0.80; 95% CI 0.72-0.90) [3]. Semaglutide also improved a range of cardiometabolic risk factors in the STEP analyses. So the weight-loss story is best read as part of a broader metabolic effect — which is exactly why the outcome trials, not just the scale, define this drug's place. The full record is on the research page.